The estimated Net Worth of Jordan Kanfer is at least 121 千$ dollars as of 3 August 2022. Mr. Kanfer owns over 7,500 units of Athenex Inc stock worth over 3,417$ and over the last 6 years he sold ATNX stock worth over 0$. In addition, he makes 117,740$ as Independent Director at Athenex Inc.
Sign up
Mr. Kanfer ATNX stock SEC Form 4 insiders trading
Jordan has made over 4 trades of the Athenex Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 7,500 units of ATNX stock worth 1,500$ on 3 August 2022.
The largest trade he's ever made was exercising 7,500 units of Athenex Inc stock on 3 August 2022 worth over 1,500$. On average, Jordan trades about 1,711 units every 128 days since 2019. As of 3 August 2022 he still owns at least 17,086 units of Athenex Inc stock.
You can see the complete history of Mr. Kanfer stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jordan Kanfer biography
Jordan S. Kanfer is Independent Director of the Company. Mr. Kanfer has served as a member of our Board since April 2019. Jordan Kanfer has served as a Managing Director, Convertible and Equity Research at Opti Capital Management, where he is responsible for all aspects of healthcare investing for both credit and equity components, since March 2018. He is currently a member of the American College of Healthcare Executives and serves on the Board of Advisors for dB Diagnostics Systems. Mr. Kanfer’s investment management experience includes working in various managerial and senior analyst roles, most recently for Arrowgrass Capital Partners from July 2014 to February 2018, and previously at TPG-Axon Capital, JANA Partners, and SAC Capital. Prior to working on the buy-side, Mr. Kanfer was a Vice President at Goldman, Sachs & Co., and previously worked in the healthcare industry in multiple consulting and operations capacities. He received an M.P.H. from the University of Massachusetts at Amherst and a B.A. in history from Yeshiva University. Kanfer serves as a valuable member of our Board due to his extensive financial experience
What is the salary of Jordan Kanfer?
As the Independent Director of Athenex Inc, the total compensation of Jordan Kanfer at Athenex Inc is 117,740$. There are 12 executives at Athenex Inc getting paid more, with Johnson Lau having the highest compensation of 4,483,840$.
How old is Jordan Kanfer?
Jordan Kanfer is 50, he's been the Independent Director of Athenex Inc since 2019. There are 16 older and 1 younger executives at Athenex Inc. The oldest executive at Athenex Inc is John Vierling, 74, who is the Independent Director.
What's Jordan Kanfer's mailing address?
Jordan's mailing address filed with the SEC is C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO, NY, 14203.
Insiders trading at Athenex Inc
Over the last 7 years, insiders at Athenex Inc have traded over 33,215,399$ worth of Athenex Inc stock and bought 5,920,005 units worth 73,651,360$ . The most active insiders traders include Advisors Llcperceptive Life...、Song Yi Zhang、Song Yi Mandra Medical Ltd .... On average, Athenex Inc executives and independent directors trade stock every 12 days with the average trade being worth of 10,843$. The most recent stock trade was executed by Joe Annoni on 22 February 2023, trading 625 units of ATNX stock currently worth 125$.
What does Athenex Inc do?
athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. the company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. our business includes medical technology innovation centers and a unique manufacturing supply chain across both china and north america. through the connected innovation and manufacturing supply chain presence, we can identify, develop and deliver proprietary medical technology across continents and multiple regulatory environments.
What does Athenex Inc's logo look like?
Complete history of Mr. Kanfer stock trades at Athenex Inc
Athenex Inc executives and stock owners
Athenex Inc executives and other stock owners filed with the SEC include:
-
Johnson Lau,
Chief Executive Officer and Chairman of the Board -
Rudolf Kwan,
Chief Medical Officer -
Jeffrey Yordon,
Chief Operating Officer and President, Athenex Pharmaceutical Division -
Randoll Sze,
Chief Financial Officer -
Simon Pedder,
Chief Business and Strategy Officer - Proprietary Products -
Jeffrey M. Yordon,
COO & Pres of Athenex Pharmaceutical Division -
Dr. Rudolf Kwan M.D., M.B., B.S.,
Chief Medical Officer -
Dr. Yiu-Nam Lau M.B.B.S., M.D., F.R.C.P., Ph.D.,
Chairman & CEO -
Benson Tsang,
Independent Director -
Stephanie Davis,
Independent Director -
Kim Campbell,
Lead Independent Director -
Jinn Wu,
Independent Director -
Jordan Kanfer,
Independent Director -
John Vierling,
Independent Director -
Manson Fok,
Director -
Robert Spiegel,
Director -
Daniel Lang,
Senior Director - Corporate Development, President - Axis Therapeutics Limited -
Tim McCarthy,
IR Contact Officer -
William Zuo,
President, China Division -
Dr. Wing-Kai Chan,
Deputy Chief Medical Officer of Orascovery & Src Kinase Platforms -
John W. Matthei,
VP of HR -
Caileigh Dougherty,
Director of Investor Relations -
Michael Smolinski Ph.D.,
Chief Scientific Officer -
Steven J. Adams,
Interim Chief Accounting Officer -
Daniel Lang M.D.,
Sr. Director of Corp. Devel. -
Jacqueline Li,
Director of Corp. Devel. & Investor Relations -
Steven Rubis,
Sr. Director of Investor Relations -
Teresa Brophy Bair,
Gen. Counsel, Sr. VP of Admin. & Corp. Sec. -
Dr. Allen Barnett,
Co-Founder & Pres Emeritus -
James Zukin,
-
Michael D Cannon,
-
J Nick Riehle,
Chief Financial Officer -
Antony Leung,
-
Song Yi Zhang,
Director -
John Koh,
Director -
Advisors Llcperceptive Life...,
-
Sheldon Trainor Degirolamo,
Director -
Timothy De Vere Cook,
See Remarks -
Teresa Brophy Bair,
General Counsel, SVP Admin. -
Joe Annoni,
Chief Financial Officer -
Steven J. Adams,
Interim Chief Acct Officer -
Michael Smolinski,
Chief Scientific Officer